Dexcom Q3 2026: Raised Guidance and a $1 Billion Buyback
As seen on the 24/7 Wall St. homepage on October 29, 2026.
Dexcom raised full-year revenue guidance again, to $5.20 billion to $5.25 billion, after topping expectations on both lines. Management also lifted non-GAAP operating margin guidance to about 24% and authorized a new $1.0 billion buyback.
Continue ReadingShow less
Dexcom beat expectations on adjusted earnings per share of $0.73 and raised full-year revenue guidance to $5.20 billion to $5.25 billion, its second raise this year.
Profitability widened across the quarter, with GAAP gross margin reaching 64.3% as the continuous glucose monitoring platform scales.
U.S. revenue grew 14% year over year, carrying growth while international revenue expanded 5%.
Sponsored
A New England Journal of Medicine trial showed meaningful outcomes for the Dexcom G7 among Type 2 diabetes patients not on insulin, a category that widens the addressable market.
The board authorized a new $1.0 billion share repurchase program alongside the earnings release, a capital allocation signal that carries weight given the company's cash position.
Mentioned: DXCM